Abstract
Purpose
Galectin-3, a member of the beta-galactoside-binding protein family, is involved in many biological processes, including cell proliferation, regulating cell cycle, angiogenesis, tumorigenesis, metastasis, etc. The aim of this study is to elucidate the relationship between galectin-3 and clinicopathological variables and to evaluate the clinical significance of serum galectin-3 in the diagnosis of pancreas carcinoma.
Methods
Galectin-3 expression in 78 pairs of pancreatic carcinoma tissues and the adjacent nontumorous tissues was tested by immunohistochemistry. The relationship between galectin-3 expression and clinical variables was analyzed. A sensitive method of time-resolved fluorescence immunological assay (TRFIA) for the detection of galectin-3 was established, and serum galectin-3 in cases with different pancreatic diseases was measured by TRFIA and ELISA. Further we compared the sensitivity and specificity of determining galectin-3, carcinoembryonic antigen (CEA) and carbohydrate antigen199 (CA199) for diagnosis of pancreatic carcinoma and assessed the complementary diagnostic value of galectin-3, CEA and CA199 for pancreatic carcinoma.
Results
Immunohistochemistry showed that galectin-3 expression was significantly higher in the human pancreatic carcinoma tissues than in the adjacent nontumorous tissues. The expression levels were correlated with the differentiation degree with the higher expression in poor differentiation tissues. Serum galectin-3 detected by both TRFIA and ELISA was much higher in patients with pancreatic carcinoma than in other groups. Serum galectin-3 was not correlated with CEA and CA199. Combined determination of these three markers has the complementary diagnostic value for human pancreatic carcinoma and may increase the diagnostic sensitivity to 97.5%.
Conclusions
Galectin-3 is overexpressed in pancreatic carcinoma tissues, and it is correlated with the tumor differentiation. Serum galectin-3 is higher in cases with pancreatic carcinoma than in benign pancreatic diseases and healthy persons. Combined determination of serum galectin-3, CEA and CA199 may improve the diagnostic power for pancreatic carcinoma.
Similar content being viewed by others
References
Abdou AG, Hammam MA, Farargy SE, Farag AG, El Shafey EN, Farouk S, Elnaidany NF (2010) Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am J Dermatopatho 32:809–814
Aceti A, Pennica A, Celestino D, Paparo SB, Caferro M, Sanguigni S, Marangi M, Sebastiani A (1988) A new serological technique, time-resolved fluoroimmunoassay (TRFIA), for the immunological diagnosis of urinary schistosomiasis. Trans R Soc Trop Med Hyg 82:445–447
Ahmad N, Gabius HJ, Sabesan S, Oscarson S, Brewer CF (2004) Thermodynamic binding studies of bivalent oligosaccharides to galectin-1, galectin-3, and the carbohydrate recognition domain of galectin-3. Glycobiology 14:817–825
Arfaoui-Toumi A, Kria-Ben Mahmoud L, Ben Hmida M, Khalfallah MT, Regaya-Mzabi S, Bouraoui S (2010) Implication of the Galectin-3 in colorectal cancer development (about 325 Tunisian patients). Bull Cancer 97:E1–E8
Barondes SH, Cooper DN, Gitt MA, Leffler H (1994) Galectins: Structure and function of a large family of animal lectins. J Biol Chem 269:20807–20810
Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Büchler MW (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49:539–549
Brustmann H (2008) Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 27:380–389
Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordón-Cardo C, Sánchez-Carbayo M (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31:277–285
Chen JH, Ni RZ, Xiao MB, Guo JG, Zhou JW (2009) Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat Dis Int 8:193–200
Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM (2010) Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 176:2067–2081
Choi JY, Cho SI, Do NY, Kang CY, Lim SC (2010) Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 39:28–34
Dagher SF, Wang JL, Patterson RJ (1995) Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 92:1213–1217
Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochim Biophys Acta 1572:285–293
Houzelstein D, Gonçalves IR, Fadden AJ, Sidhu SS, Cooper DN, Drickamer K, Leffler H, Poirier F (2004) Phylogenetic analysis of the vertebrate galectin family. Mol Biol Evol 21:1177–1187
Inohara H, Akahani S, Raz A (1998) Galectin-3 stimulates cell proliferation. Exp Cell Res 245:294–302
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E (2002) Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31:428–433
Kim YS, Jung JA, Kim HJ, Ahn YH, Yoo JS, Oh S, Cho C, Yoo HS, Ko JH (2011) Galectin-3 binding protein promotes cell motility in colon cancer by stimulating the shedding of protein tyrosine phosphatase kappa by proprotein convertase 5. Biochem Biophys Res Commun 404:96–102
Koo JS, Jung W (2011) Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 52:89–97
Lin HM, Moon BK, Yu F, Kim HR (2000) Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 21:1941–1945
Maple PA, Jones CS, Andrews NJ (2001) Time resolved fluorometric immunoassay, using europium labelled antihuman IgG, for the detection of human tetanus antitoxin in serum. J Clin Pathol 54:812–815
Markowska AI, Liu FT, Panjwani N (2010) Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 207:1981–1993
Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064–4068
Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Iacobelli S (2000) Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 85:545–554
Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T (2008) Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 38:1098–1111
Merlin J, Stechly L, de Beaucé S, Monté D, Leteurtre E, van Seuningen I, Huet G, Pigny P (2011) Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells. Oncogene 30:2514–2525
Michl P, Pauls S, Gress TM (2006) Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 20:227–251
Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909
Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H (2006) Reduced Galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 26:1369–1376
Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, Pazerini G, Carmi P (1990) Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 46:871–877
Righi A, Jin L, Zhang S, Stilling G, Scheithauer BW, Kovacs K, Lloyd RV (2010) Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol 326:8–14
Saffar H, Sanii S, Heshmat R, Haghpanah V, Larijani B, Rajabiani A, Azimi S, Tavangar SM (2011) Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma. Am J Clin Pathol 135:454–460
Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H, Kanayama HO (2010) Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 57:152–157
Senapati S, Chaturvedi P, Chaney WG, Chakraborty S, Gnanapragassam VS, Sasson AR, Batra SK (2011) Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res 17:267–274
Szöke T, Kayser K, Trojan I, Kayser G, Furak J, Tiszlavicz L, Baumhäkel JD, Gabius HJ (2007) The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur J Cardiothorac Surg 31:783–787
Takenaka Y, Fukumori T, Raz A (2004) Galectin-3 and metastasis. Glycoconj J 19:543–549
Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, Yu LG (2009) Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res 69:6799–6806
Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, Yu LG (2010) Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer 9:154
Acknowledgments
This work was supported by grants from the Foundation for Talents in Six Fields of Jiangsu Province (No. 2006073), the Health Project of Jiangsu Province (H200923), and the Social Development Foundation of Nantong City (S2007028 and S2010012).
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Ling Xie and Wen-Kai Ni contributed equally to this work.
Rights and permissions
About this article
Cite this article
Xie, L., Ni, WK., Chen, XD. et al. The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol 138, 1035–1043 (2012). https://doi.org/10.1007/s00432-012-1178-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1178-2